Clinical

The approval comes following phase 2 results of 119 patients who participated in the IMvigor210 study.

The European Respiratory Society and the American Thoracic Society have conducted a comprehensive review of evidence of managing exacerbations of chronic obstructive pulmonary disease in order to create a guideline of clinical recommendations.

A new collaboration between the Duke Clinical Research Institute, Duke University’s MURDOCK Study, and Boehringer Ingelheim Pharmaceuticals Inc will try to better understand how chronic obstructive pulmonary disease progresses in the real world.

Exposure to tobacco smoke as a fetus or during early childhood can cause genetic changes that can increase a child’s risk of developing acute lymphoblastic leukemia (ALL).

Clinical pathways can successfully be used to drive physicians to choose a less costly regimen when the efficacy and toxicity of different treatment regimens for metastatic colorectal cancer are comparable, according to a study in the Journal of Oncology Practice.

A study presented at the annual meeting of the American Association for Cancer Research predicts a shift in the number and the pattern of cancer incidence among those infected with the human immunodeficiency virus (HIV).

Patients with chorea associated with Huntington’s disease have the first new treatment in nearly a decade. The FDA has approved Teva Pharmaceutical Industries Ltd’s Austedo (deutetrabenazine) for the treatment of chorea, which affects nearly 90% of patients with Huntington's.

The patient voice is becoming more important as healthcare moves to a value-based, patient-centered system of care, but just amplifying the patient voice is not enough. There needs to not only be amplification, but also a constructive response from the health system, said Thomas Lee, MD, chief medical officer at Press Ganey, during his presentation at the National Quality Forum Annual Conference.

The 5-year survival estimate from a study evaluating nivolumab in a subset of patients with advanced non-small cell lung cancer (NSCLC) is significantly longer following treatment discontinuation.

Behind the scenes there are a number of advances that Patricia Flatley Brennan, RN, PhD, director of the National Library of Medicine, would like to see take place to make it easier to get literature into people's hands.

The full approval comes in less than 2 years of the drug's accelerated approval by the FDA.

Being blind, intellectually disabled, or having a spinal cord injury can reduce the probability of a person being screened for colorectal cancer.

Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused clinical review on the topic of the PCSK9 inhibitor Repatha (evolocumab), and its impact on low-density lipoprotein cholesterol (LDL-C).